- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.60 Å
- Oligo State
- monomer
- Ligands
- 3 x CLR: CHOLESTEROL(Non-covalent)
- 1 x 8IM: 2-[2-[2-[2-[2-[2-[4-[4-[2-[7-azanyl-4-(furan-2-yl)-3,5,6,8,10,11-hexazatricyclo[7.3.0.0^{2,6}]dodeca-1(9),2,4,7,11-pentaen-10-yl]ethyl]piperazin-1-yl]phenoxy]ethanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]-~{N}-[5-[2,2-bis(fluoranyl)-4,6,10,12-tetramethyl-1,3-diaza-2$l^{4}-boratricyclo[7.3.0.0^{3,7}]dodeca-4,6,9,11-tetraen-8-yl]pentyl]ethanamide(Non-covalent)
8IM.4: 16 residues within 4Å:- Chain A: S.92, T.93, L.110, F.193, E.194, M.202, W.367, L.370, H.371, N.374, H.385, A.386, L.388, M.391, Y.392, I.395
13 PLIP interactions:13 interactions with chain A- Hydrophobic interactions: A:L.110, A:F.193, A:W.367, A:L.370, A:H.385, A:I.395
- Hydrogen bonds: A:N.374, A:N.374
- Water bridges: A:K.178
- Salt bridges: A:E.194
- pi-Stacking: A:F.193, A:F.193, A:H.385
- 25 x OLA: OLEIC ACID(Non-covalent)(Non-functional Binders)
OLA.5: 4 residues within 4Å:- Chain A: F.118, A.122, I.125
- Ligands: OLA.15
Ligand excluded by PLIPOLA.6: 6 residues within 4Å:- Chain A: I.28, S.31, S.32, I.35, T.36
- Ligands: OLA.21
Ligand excluded by PLIPOLA.7: 10 residues within 4Å:- Chain A: V.82, P.86, I.89, T.90, T.93, F.95
- Ligands: OLA.8, OLA.9, OLA.21, OLC.33
Ligand excluded by PLIPOLA.8: 3 residues within 4Å:- Ligands: OLA.7, OLA.9, OLC.33
Ligand excluded by PLIPOLA.9: 3 residues within 4Å:- Ligands: OLA.7, OLA.8, OLA.21
Ligand excluded by PLIPOLA.10: 3 residues within 4Å:- Chain A: F.226, V.350, K.354
Ligand excluded by PLIPOLA.11: 6 residues within 4Å:- Chain A: G.30, S.31, Y.34, L.388, Y.392, V.396
Ligand excluded by PLIPOLA.12: 4 residues within 4Å:- Chain A: I.28, M.29, S.32, V.33
Ligand excluded by PLIPOLA.13: 1 residues within 4Å:- Ligands: OLA.29
Ligand excluded by PLIPOLA.14: 3 residues within 4Å:- Chain A: I.358, G.361
- Ligands: OLA.23
Ligand excluded by PLIPOLA.15: 5 residues within 4Å:- Chain A: L.121, I.125, L.217, V.221
- Ligands: OLA.5
Ligand excluded by PLIPOLA.16: 1 residues within 4Å:- Chain A: W.389
Ligand excluded by PLIPOLA.17: 4 residues within 4Å:- Chain A: C.53, I.78, V.82
- Ligands: OLA.25
Ligand excluded by PLIPOLA.18: 2 residues within 4Å:- Ligands: CLR.3, OLA.19
Ligand excluded by PLIPOLA.19: 4 residues within 4Å:- Chain A: M.165
- Ligands: CLR.3, OLA.18, OLA.28
Ligand excluded by PLIPOLA.20: 4 residues within 4Å:- Chain A: Y.204, F.208, L.212
- Ligands: OLC.31
Ligand excluded by PLIPOLA.21: 5 residues within 4Å:- Chain A: I.35, L.39
- Ligands: OLA.6, OLA.7, OLA.9
Ligand excluded by PLIPOLA.22: 4 residues within 4Å:- Chain A: L.44, V.404, F.407
- Ligands: OLA.24
Ligand excluded by PLIPOLA.23: 3 residues within 4Å:- Chain A: A.357, G.361
- Ligands: OLA.14
Ligand excluded by PLIPOLA.24: 4 residues within 4Å:- Chain A: T.400, F.407, I.408
- Ligands: OLA.22
Ligand excluded by PLIPOLA.25: 6 residues within 4Å:- Chain A: V.56, V.71, A.75, I.78
- Ligands: OLA.17, OLC.32
Ligand excluded by PLIPOLA.26: 3 residues within 4Å:- Chain A: W.389, L.390
- Ligands: CLR.2
Ligand excluded by PLIPOLA.27: 8 residues within 4Å:- Chain A: K.147, W.154, V.155, F.158, A.159, L.162
- Ligands: OLA.28, OLC.32
Ligand excluded by PLIPOLA.28: 5 residues within 4Å:- Chain A: F.158, L.162, M.165
- Ligands: OLA.19, OLA.27
Ligand excluded by PLIPOLA.29: 6 residues within 4Å:- Chain A: L.216, G.220, L.223, R.224, L.227
- Ligands: OLA.13
Ligand excluded by PLIP- 4 x OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate(Non-covalent)
OLC.30: 5 residues within 4Å:- Chain A: G.148, I.152, A.159, T.163
- Ligands: PEG.35
3 PLIP interactions:3 interactions with chain A- Hydrophobic interactions: A:I.152, A:I.152, A:A.159
OLC.31: 4 residues within 4Å:- Chain A: Y.204, F.208, A.209
- Ligands: OLA.20
3 PLIP interactions:3 interactions with chain A- Hydrophobic interactions: A:Y.204, A:F.208, A:A.209
OLC.32: 7 residues within 4Å:- Chain A: Y.68, V.71, A.75, K.147, W.154
- Ligands: OLA.25, OLA.27
3 PLIP interactions:3 interactions with chain A- Hydrophobic interactions: A:A.75, A:W.154, A:W.154
OLC.33: 8 residues within 4Å:- Chain A: L.83, F.87, T.90, F.95, C.96
- Ligands: CLR.3, OLA.7, OLA.8
5 PLIP interactions:5 interactions with chain A- Hydrophobic interactions: A:L.83, A:F.87, A:T.90, A:F.95
- Water bridges: A:C.96
- 2 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Claff, T. et al., Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A 2A Receptor with Preladenant Conjugates. Angew.Chem.Int.Ed.Engl. (2022)
- Release Date
- 2022-03-02
- Peptides
- Adenosine receptor A2a,Soluble cytochrome b562,Adenosine receptor A2a: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A - Membrane
-
We predict this structure to be a membrane protein.
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.60 Å
- Oligo State
- monomer
- Ligands
- 3 x CLR: CHOLESTEROL(Non-covalent)
- 1 x 8IM: 2-[2-[2-[2-[2-[2-[4-[4-[2-[7-azanyl-4-(furan-2-yl)-3,5,6,8,10,11-hexazatricyclo[7.3.0.0^{2,6}]dodeca-1(9),2,4,7,11-pentaen-10-yl]ethyl]piperazin-1-yl]phenoxy]ethanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]-~{N}-[5-[2,2-bis(fluoranyl)-4,6,10,12-tetramethyl-1,3-diaza-2$l^{4}-boratricyclo[7.3.0.0^{3,7}]dodeca-4,6,9,11-tetraen-8-yl]pentyl]ethanamide(Non-covalent)
- 25 x OLA: OLEIC ACID(Non-covalent)(Non-functional Binders)
- 4 x OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate(Non-covalent)
- 2 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Claff, T. et al., Single Stabilizing Point Mutation Enables High-Resolution Co-Crystal Structures of the Adenosine A 2A Receptor with Preladenant Conjugates. Angew.Chem.Int.Ed.Engl. (2022)
- Release Date
- 2022-03-02
- Peptides
- Adenosine receptor A2a,Soluble cytochrome b562,Adenosine receptor A2a: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A - Membrane
-
We predict this structure to be a membrane protein.